Evidence map›Paper›PMID 41483418›Full record

ArticleClinical and experimental medicine2026

Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.

Yue Li, Bin Zhao, Wenzhi Gao, Yucai Wu, Tai Tian, Shimeng Zhao, Jilong Zhang, Ran Li, Shiming He, Yanqing Gong and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Yue LiDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Bin ZhaoDepartment of Urology, The Third Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Wenzhi GaoDepartment of Urology, Peking University First Hospital - Miyun Hospital, Beijing, 100034, China.
Yucai WuDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Tai TianDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Shimeng ZhaoDepartment of Urology, The Third Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Jilong ZhangDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Ran LiDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Shiming HeDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Yanqing GongDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Jianguo MaDepartment of Urology, The Third Hospital of Hebei Medical University, Shijiazhuang, 050000, China. mjg1971@aliyun.com.
Xuesong LiDepartment of Urology, Peking University First Hospital, Beijing, 100034, China. pineneedle@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41483418
PMCPMC12764493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.